<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00684970</url>
  </required_header>
  <id_info>
    <org_study_id>TLH-202</org_study_id>
    <nct_id>NCT00684970</nct_id>
  </id_info>
  <brief_title>Phase IIB Clinical Trial of Hamsa-1™ in Metastatic Castration Resistant Prostate Cancer (CRPC)</brief_title>
  <acronym>TLH-202</acronym>
  <official_title>A Phase IIB Clinical Trial of the Anti-Angiogenic Drug Combination Hamsa-1™ in Metastatic Castration Resistant Prostate Cancer (CRPC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tiltan Pharma Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tiltan Pharma Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hamsa-1™ is an anti-angiogenic drug combination designed for the treatment of cancer. The
      investigational product Hamsa-1™ comprises of four well-known active components. The therapy
      is administrated at a unique dosing regimen that was found to be effective and advantageous
      in terms of safety.The product is formulated as an oral suspension, conveniently
      administrated by the patients at home and not requiring medical staff assistance. This Phase
      IIb clinical trial aims to evaluate the efficacy of Hamsa-1™ for the treatment of metastatic
      Castration Resistant Prostate Cancer (CRPC) patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2009</start_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS) measured 24 weeks after treatment initiation</measure>
    <time_frame>24 weeks and up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival, Time to PSA Progression, PSA Response, Pain Response measured in evaluable patients.</measure>
    <time_frame>52 weeks and up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Metastatic Castration Resistant Prostate Cancer (CRPC)</condition>
  <arm_group>
    <arm_group_label>Hamsa-1™ TL-118</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Once daily Hamsa-1™ TL-118 (single arm)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hamsa-1™ TL-118</intervention_name>
    <description>Once daily Hamsa-1™ TL-118</description>
    <arm_group_label>Hamsa-1™ TL-118</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects willing and able to give written informed consent

          2. Confirmed metastatic castration resistant prostate cancer and rising PSA

          3. ECOG performance status ≤ 1

          4. Adequate renal function, hepatic function and bone marrow reserve.

          5. Subjects capable of swallowing.

        Exclusion Criteria:

          1. Hypersensitivity to one or more of the Hamsa-1™ active components

          2. Glucose-6-phosphate-dehydrogenase deficiency (G6PD)

          3. Subjects with a clinically significant or unstable medical condition that would
             preclude safe and complete study participation

          4. Subjects who received any investigational medication, antineoplastic therapy, or any
             significant change in treatment within 1 month prior to screening

          5. Subjects with visceral metastases (e.g. liver, lung)

          6. Subjects who received more than 2 prior chemotherapies for the treatment of prostate
             cancer

          7. Subjects suffering from circumstances likely to interfere with absorption of orally
             administrated drugs

          8. Subjects unwilling to or unable to comply with study protocol
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan Goldstaub, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Chief Operating Officer, Tiltan Pharma LtD</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dan Goldstaub, Ph.D.</last_name>
    <phone>972-54-555-8573</phone>
    <email>dan@tiltanpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bnei Tzion Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Ofer Nativ</last_name>
      <email>ofer.nativ@b-zion.org.il</email>
    </contact>
    <investigator>
      <last_name>Prof. Ofer Nativ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Avivit Peer, MD</last_name>
      <email>a_peer@rambam.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Dr. Avivit Peer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Raanan Berger, M.D.</last_name>
      <email>Raanan.Berger@sheba.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Dr. Raanan Berger, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center</name>
      <address>
        <city>Tel-Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Eliahu Gez, MD</last_name>
      <email>eliahug@tasmc.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Dr. Eliahu Gez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asaf Harofe Medical Center</name>
      <address>
        <city>Tzrifin</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Avishay Sella, MD</last_name>
      <email>Dr.AvishaySella@asaf.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Prof. Avishay Sella, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2008</study_first_submitted>
  <study_first_submitted_qc>May 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2008</study_first_posted>
  <last_update_submitted>December 4, 2013</last_update_submitted>
  <last_update_submitted_qc>December 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CRPC</keyword>
  <keyword>HRPC</keyword>
  <keyword>metastatic prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cimetidine</mesh_term>
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Sulfasalazine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

